PROGRAM CHAIRS
Nosheen Reza, MD, FACC, FHFSA
Assistant Professor of Medicine
Penn Center for Inherited Cardiovascular Disease
Section of Advanced Heart Failure, Transplantation, and Mechanical Support
Penn Medicine
Philadelphia, Pennsylvania
Muthiah Vaduganathan, MD, MPH
Co-Director
Center for Cardiometabolic Implementation Science
Brigham and Women’s Hospital
Harvard Medical School
Boston, Massachusetts
PROGRAM OVERVIEW
This evidence-based symposium integrates research and practical tools to enhance understanding of the pathophysiological link between cardiovascular disease (CVD) and chronic kidney disease (CKD). Participants will explore evidence-based CKD screening for patients with CVD or elevated CV risk. Through case studies and patient scenarios, the program demonstrates how to develop guideline-based treatment plans incorporating novel therapies for patients with CVD and comorbid CKD. Attendees will gain practical tools to implement a holistic, patient-centered care model that improves communication and encourages shared decision-making.
TARGET AUDIENCE
This educational activity is tailored for general cardiologists and advanced practice providers (APPs) in cardiology who manage patients at high risk for chronic kidney disease (CKD) and play a pivotal role in cardiovascular care.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Describe the pathophysiologic relationship between CVD and CKD and provide evidence-based CKD screening for patients with CVD or CV risk factors
- Create evidence-based guideline-informed treatment plans for the use of novel CMD therapies in patients with CVD, who may also have co-morbid CKD
- Apply a holistic, patient-centric care model that streamlines communication across an MDT and includes the patient’s perspective through SDM to enhance care for patients with CVD and co-morbid CKD
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hour.
ACCME INNOVATION PARTNER
Med Learning Group (MLG) is proud to be recognized as an ACCME Innovation Partner, leading the way in simplifying CME for physicians. As an Innovation Partner, MLG will be working with the ACCME by submitting credits directly to CME Passport.
ACCME INNOVATION PARTNER DISCLAIMER
Upon your acceptance in the evaluation and completion of this CME activity, Med Learning Group will share your completion information and certain personal details (eg, name, National Provider Identifier, birthdate MM/DD) with the ACCME for inclusion in your CME Passport transcript and, as applicable, reporting to certifying, licensing, or other regulatory authorities you specify.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Nosheen Reza, MD | Consulting Fees: Zoll Medical, Roche, American Regent, Idorsia, Novo Nordisk, AstraZeneca, and Bristol Myers Squibb. Contracted Research: Bristol Myers Squibb. |
| Muthiah Vaduganathan, MD | Consulting Fees: Alnylam Pharmaceuticals, American Regent, Amgen, AstraZeneca, Bayer AG, Baxter Healthcare, Bristol Myers Squibb, Boehringer Ingelheim, Chiesi Farmaceutici, Cytokinetics, Esperion, Fresenius Medical Care, Idorsia, Lexicon, Merck, Milestone, Novartis, Novo Nordisk, Pharmacosmos, Recordati, Relypsa, Roche Diagnostics, Sanofi, and Tricog Health. Contracted Research: Amgen, AstraZeneca, Bayer AG, Boehringer Ingelheim, Galmed, Impulse Dynamics, Novartis, Occlutech, and Pharmacosmos. |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Chris Drury, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Joan Duer-Hefele, RN, MA, CCRC has nothing to disclose.
- Ana Maria Albino, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Jessica Feygin-Samuels, Program Manager for Med Learning Group, has nothing to disclose.
- Kristen Marks, Program Coordinator for Med Learning Group, has nothing to disclose.
- Russie Allen, MM, Accreditation and Outcomes Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Expert staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: December 01, 2025
EXPIRATION DATE: December 01, 2026
Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
